Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion.
## Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Maintenance of healing of erosive esophagitis
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Treatment of duodenal ulcers
* Treatment of gastric ulcers
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily.
* **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose is 40 mg orally or intravenously twice daily. Doses may be increased up to 240 mg intravenously daily or 40 mg orally up to three times daily. Doses over 80 mg daily should be divided.
* **Duodenal ulcers:** 40 mg orally once daily for up to 4 weeks.
* **Gastric ulcers:** 40 mg orally once daily for up to 8 weeks.
## Pediatric Dosing
* **12 years and older:**
* **Erosive esophagitis:** 40 mg orally once daily.
* **GERD (symptomatic):** 20 mg orally once daily. Doses may be increased to 40 mg once daily if needed.
* **Less than 12 years:** Dosing is not well-established in this population for all indications. Consult specific pediatric guidelines.
## Dose Adjustments
No dose adjustment is generally needed for hepatic impairment when using the oral formulation. For intravenous administration in severe hepatic impairment, consider a dose of 20 mg once daily. Renal impairment does not typically require dose adjustment.
## Contraindications
* Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, vomiting, dizziness.
* **Serious:** *Clostridioides difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with long-term use, hypomagnesemia, vitamin B12 deficiency, lupus erythematosus (cutaneous and systemic).
## Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Antiretrovirals (e.g., rilpivirine, atazanavir), antifungals (e.g., ketoconazole, itraconazole), iron salts, mycophenolate mofetil. Monitor for efficacy of the coadministered drug.
* **Methotrexate:** PPIs may increase methotrexate levels. Consider PPI discontinuation during methotrexate treatment.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Monitor for altered levels of coadministered drugs like clopidogrel.
## Monitoring
* Assess for improvement of GERD symptoms.
* Monitor for signs and symptoms of *C. difficile*-associated diarrhea.
* Monitor serum magnesium levels, especially in patients on long-term therapy or taking concomitant medications that can lower magnesium (e.g., diuretics).
* Consider vitamin B12 levels in patients on long-term therapy or with risk factors for B12 deficiency.
* Evaluate bone mineral density in patients at risk for osteoporosis.
## Clinical Pearls
* Oral pantoprazole should be taken at least 30 minutes before a meal.
* The 40 mg oral dose is typically used for healing erosive esophagitis and hypersecretory conditions, while 20 mg is often used for symptomatic GERD relief in children.
* Long-term use of PPIs has been associated with an increased risk of certain adverse events; use the lowest effective dose for the shortest duration necessary.
***
*This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete details before making any treatment decisions. Dosing and recommendations may vary based on patient-specific factors and local protocols.*
